Revenue
2018
2019
2020
2021
2022
2023
2024
2025
HERON THERAPEUTICS, INC. /DE/ (HRTX)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $154.9M | $144.3M | $127.0M | $107.7M | $86.3M | $88.6M | $146.0M | $77.5M | $30.8M | $1.3M | — | — | — | — | — | — | — |
| Gross profit | $113.6M | $105.6M | $61.9M | $52.8M | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Research & development | $12.4M | $16.7M | $39.1M | $82.7M | $130.8M | $174.5M | $167.4M | $140.0M | $138.6M | $103.1M | $61.2M | $54.8M | $32.5M | $15.2M | $8.2M | $7.3M | $7.8M |
| Operating expenses | — | — | — | — | — | — | — | $261.4M | $225.3M | $172.2M | $96.9M | $74.6M | $54.5M | $23.8M | $11.7M | $11.2M | $11.5M |
| Operating income | −$2.5M | −$11.5M | −$110.6M | −$174.7M | −$217.8M | −$228.2M | −$210.7M | −$183.9M | −$194.6M | −$170.9M | −$96.9M | −$74.6M | −$54.5M | −$23.8M | −$11.1M | −$9.9M | −$10.2M |
| EBITDAderived | −$224,000 | −$9.0M | −$107.7M | −$171.8M | −$214.8M | −$225.3M | −$208.7M | −$182.4M | −$193.0M | −$169.8M | −$96.2M | −$74.0M | −$54.1M | −$23.6M | −$10.9M | −$9.7M | −$9.9M |
| Net income | −$20.2M | −$13.6M | −$110.6M | −$182.0M | −$220.7M | −$227.3M | −$204.7M | −$178.8M | −$197.5M | −$173.1M | −$97.6M | −$76.4M | −$55.3M | −$23.3M | −$11.8M | −$7.3M | −$10.0M |
| Basic EPSper diluted share | -$0.12 | -$0.09 | -$0.80 | -$1.67 | -$2.24 | -$2.50 | -$2.50 | -$2.44 | -$3.65 | -$4.56 | -$2.95 | -$2.87 | -$3.42 | -$1.91 | -$1.96 | -$0.19 | -$0.31 |
| Diluted EPSper diluted share | -$0.12 | -$0.09 | -$0.80 | -$1.67 | -$2.24 | -$2.50 | -$2.50 | -$2.44 | -$3.65 | -$4.56 | -$2.95 | -$2.87 | -$3.42 | -$1.91 | -$1.96 | -$0.19 | -$0.31 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Aug 8, 2025Form 4 | Morgan AdamDirector | BuyCommon Stock · indirect | 1.77M | $1.50 | $2.65M | 8.75M |
| Aug 8, 2025Form 4 | Morgan AdamDirector | BuySeries A Convertible Preferred Stock · derivative · indirect | 70.0K | $15.00 | $1.05M | 70.0K |
| Aug 8, 2025Form 4 | Rosen David Efraim +1TenPercentOwner | BuyCommon Stock, par value $0.01 per share ("Common Stock") · indirect | 2.39M | $1.50 | $3.58M | 29.10M |
| Aug 8, 2025Form 4 | Rosen David Efraim +1TenPercentOwner | BuySeries A Convertible Preferred Stock ("Preferred Shares") · derivative · indirect | — | $15.00 | — | — |
| Aug 8, 2025Form 4 | Rosen David Efraim +1TenPercentOwner | BuyConvertible Senior Unsecured Promissory Notes ("Notes") · derivative · indirect | 94.6K | $33.25M | $35.00M | 94.6K |